Provided by Tiger Trade Technology Pte. Ltd.

Revolution Medicines, Inc.

209.87
+4.302.09%
Post-market: 210.500.6300+0.30%18:24 EDT
Volume:1.83M
Turnover:381.73M
Market Cap:44.98B
PE:-23.52
High:210.26
Open:204.64
Low:202.54
Close:205.57
52wk High:224.31
52wk Low:37.88
Shares:214.34M
Float Shares:184.00M
Volume Ratio:0.73
T/O Rate:1.00%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.9212
EPS(LYR):-5.9502
ROE:-79.09%
ROA:-30.12%
PB:17.26
PE(LYR):-35.27

Loading ...

Revolution Medicines Announces Asco Plenary Presentation Highlighting Unprecedented Results From Pivotal Phase 3 Rasolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer

THOMSON REUTERS
·
May 31

CORRECTED-Revolution's pancreatic cancer drug doubles survival, boosts quality of life

Reuters
·
May 31

Revolution Medicines Chief Global Commercialization Officer Anthony Mancini disposes of common shares worth $478,465.61

Reuters
·
May 29

Analysts Conflicted on These Healthcare Names: CVS Health (CVS), Revolution Medicines (RVMD) and Neumora Therapeutics, Inc. (NMRA)

TIPRANKS
·
May 27

What Revolution Medicines (RVMD)'s Phase 3 Daraxonrasib Survival Data Means For Shareholders

Simply Wall St.
·
May 24

Revolution Medicines Initiated at Market Perform by Bernstein

Dow Jones
·
May 22

Bernstein Initiates Revolution Medicines at Market Perform

MT Newswires Live
·
May 22

Bernstein starts Revolution Medicines at Market Perform, says upside baked in

TIPRANKS
·
May 22

Revolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO Presentation

GlobeNewswire
·
May 22

Cantargia Q1 FY26 operating loss narrows to SEK 36.9 million; net sales rise to SEK 0.5 million

Reuters
·
May 19

Revolution Medicines Coverage Assumed by Truist Securities at Buy

Dow Jones
·
May 19

Revolution Medicines Advances Daraxonrasib Into Phase 3 Pancreatic Cancer Trial, Raising Long-Term Upside Potential

TIPRANKS
·
May 15

US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug

Reuters
·
May 14

LifeSci Capital Sticks to Their Buy Rating for Revolution Medicines (RVMD)

TIPRANKS
·
May 10

Alphabet Reports Stake In PayPay And CME Group, Dissolves In Dexcom

Reuters
·
May 08

Revolution Medicines Warrants: Balancing Dilution Risk and Potential Worthlessness Ahead of 2026 Expiry

TIPRANKS
·
May 08

Revolution Medicines price target raised to $185 from $170 at BofA

TIPRANKS
·
May 08

Evercore ISI Sticks to Their Buy Rating for Revolution Medicines (RVMD)

TIPRANKS
·
May 07

Revolution Medicines: Buy Rating Backed by Strong Daraxon Launch Signals and Pancreatic Cancer Upside Optionality

TIPRANKS
·
May 07

RBC Capital Adjusts Revolution Medicines Price Target to $165 From $162, Maintains Outperform Speculative Risk Rating

MT Newswires Live
·
May 07